tradingkey.logo

Trinity Biotech PLC

TRIB
1.020USD
-0.260-20.31%
收盤 12/24, 13:00美東報價延遲15分鐘
8.46M總市值
虧損本益比TTM

Trinity Biotech PLC

1.020
-0.260-20.31%

關於 Trinity Biotech PLC 公司

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Trinity Biotech PLC簡介

公司代碼TRIB
公司名稱Trinity Biotech PLC
上市日期Oct 21, 1992
CEOGillard (John)
員工數量- -
證券類型Depository Receipt
年結日Oct 21
公司地址Ida Business Park, Bray, Co Wicklow
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Ireland
郵編18
電話01135312955111
網址https://www.trinitybiotech.com/
公司代碼TRIB
上市日期Oct 21, 1992
CEOGillard (John)

Trinity Biotech PLC公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Matthew Wictome
Dr. Matthew Wictome
Vice President - Quality and Regulatory Affairs
Vice President - Quality and Regulatory Affairs
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
地區USD
名稱
營收
佔比
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
業務
地區
業務USD
名稱
營收
佔比
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

股東統計

更新時間: 11月21日 週五
更新時間: 11月21日 週五
持股股東
股東類型
持股股東
持股股東
佔比
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
持股股東
持股股東
佔比
MiCo IVD Holdings, LLC
60.60%
Perceptive Advisors LLC
48.47%
Hunter Associates Investment Management LLC
13.19%
Renaissance Technologies LLC
4.64%
Citadel Advisors LLC
1.07%
股東類型
持股股東
佔比
Corporation
60.06%
Private Equity
48.04%
Investment Advisor
3.34%
Hedge Fund
1.33%
Research Firm
0.14%
Investment Advisor/Hedge Fund
0.13%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
2023Q2
47
3.98M
52.08%
+190.03K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
MiCo IVD Holdings, LLC
447.59K
2.4%
--
--
Dec 17, 2024
Perceptive Advisors LLC
358.00K
1.92%
+358.00K
--
Jun 30, 2025
Hunter Associates Investment Management LLC
87.58K
0.47%
+12.56K
+16.74%
Jun 30, 2025
Renaissance Technologies LLC
11.39K
0.06%
-3.94K
-25.70%
Jun 30, 2025
Two Sigma Investments, LP
3.02K
0.02%
-3.51K
-53.79%
Jun 30, 2025
Moss Adams Wealth Advisors LLC
5.13K
0.03%
--
--
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
4.46K
0.02%
--
--
Jun 30, 2025
Raymond James & Associates, Inc.
5.07K
0.03%
--
--
Jun 30, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
公告日期
類型
比率
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1

常見問題

Trinity Biotech PLC的前五大股東是誰?

Trinity Biotech PLC的前五大股東如下:
MiCo IVD Holdings, LLC
持有股份:447.59K
佔總股份比例:2.40%。
Perceptive Advisors LLC
持有股份:358.00K
佔總股份比例:1.92%。
Hunter Associates Investment Management LLC
持有股份:87.58K
佔總股份比例:0.47%。
Renaissance Technologies LLC
持有股份:11.39K
佔總股份比例:0.06%。
Two Sigma Investments, LP
持有股份:3.02K
佔總股份比例:0.02%。

Trinity Biotech PLC的前三大股東類型是什麼?

Trinity Biotech PLC 的前三大股東類型分別是:
MiCo IVD Holdings, LLC
Perceptive Advisors LLC
Hunter Associates Investment Management LLC

有多少機構持有Trinity Biotech PLC(TRIB)的股份?

截至2025Q3,共有51家機構持有Trinity Biotech PLC的股份,合計持有的股份價值約為972.36K,占公司總股份的12.90% 。與2025Q2相比,機構持股有所增加,增幅為-4.08%。

哪個業務部門對Trinity Biotech PLC的收入貢獻最大?

在FY2023,Clinical Laboratory業務部門對Trinity Biotech PLC的收入貢獻最大,創收42.29M,占總收入的74.41% 。
KeyAI